Aricept Vascular Dementia Study Yields Unexpectedly High Mortality
This article was originally published in The Pink Sheet Daily
Despite high mortality rate in study of Pfizer/Eisai’s donepezil for vascular dementia, combined analysis shows no statistically significant difference in mortality rates.
You may also be interested in...
Eisai has submitted a reformatted electronic supplemental new drug application for Aricept (donepezil), the firm announced Dec. 19
Health plans should account for the rise in utilization that occurs with use of mail-order pharmacy when deciding if mail order saves money, Ohio Public Employees Retirement System Director of Healthcare Scott Streator said at the recent Academy of Managed Care Pharmacy Educational Conference in Chicago
Declines in Lipitor's prescription volume due to the presence of generic simvastatin are being offset by price increases, Pfizer says